2024 was an eventful year for the South Korean biopharma industry with the emergence of several key themes that look set to carry over into the new year.
The sector is facing a new growth chapter fuelled by increasing US approvals of Korea-originated new drugs, robust R&D activities, licensing deals and mergers and acquisitions involving
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?